Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38803 | 1.00 | SLC7A5 (0.49) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL19667341 | 0.90 | SLC7A5 (0.55) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL2703289 | 0.90 | SLC7A5 (0.55) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL38535 | 0.90 | SLC7A5 (0.55) | SLC7A5PTGS1PKMALPIXIAP | |
| Hydrochloric Acid SCHEMBL10477486 | 0.88 | SLC7A5 (0.53) | SLC7A5PTGS1PKMALPIXIAP | |
| Hydrochloric Acid SCHEMBL10477485 | 0.88 | SLC7A5 (0.53) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL5281460 | 0.88 | SLC7A5 (0.57) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL20889265 | 0.82 | SLC7A5 (0.47) | SLC7A5PTGS1PKMALPIXIAP | |
| Phenylalanine SCHEMBL15966897 | 0.82 | SLC7A5 (0.71) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL8767255 | 0.80 | SLC7A5 (0.50) | SLC7A5PTGS1PKMALPIXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397314-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240156892-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-11931397-B2 | Methods and compositions for the treatment of Sengers syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-20240024408-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4302829-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-1599216-A2 | METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005072295-A2 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050158373-A1 | Small peptides that are energy-independent, non-endocytotic; nontoxic, peptidase resistant | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-21 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040248808-A1 | Methods for preventing mitochondrial permeability transition | PUBLIC HEALTH SERVICE/NATIONAL INSTITUTES OF HEALTH (NIH) | 2004-12-09 | — | — | US | disclosed |
| WO-2004070054-A2 | METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024408-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | CLN6, PRPH, TSG101 | SLC7A5 1910/4885PTGS1 2630/4885PKM 3319/4885 |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | CRYAA, CRYAB, IAPP | SLC7A5 1710/4885PTGS1 996/4885PKM 2407/4885 |
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | OAT, TFAM, OTC | SLC7A5 1955/4885PTGS1 2772/4885PKM 589/4885 |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | SLC7A5 2206/4885PTGS1 3381/4885PKM 894/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | SLC7A5 3230/4885PTGS1 2951/4885PKM 2444/4885 |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | MTPN, CKMT1A; CKMT1B, TFAM | SLC7A5 2849/4885PTGS1 3597/4885PKM 369/4885 |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | OPRL1, TSG101, NGF | SLC7A5 269/4885PTGS1 4174/4885PKM 3803/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | SLC7A5 1049/4885PTGS1 2918/4885PKM 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.